{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T18:33:04Z","timestamp":1775327584326,"version":"3.50.1"},"reference-count":28,"publisher":"Japanese Society of Internal Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,3,15]]},"DOI":"10.2169\/internalmedicine.5182-24","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T22:07:24Z","timestamp":1754518044000},"page":"795-801","source":"Crossref","is-referenced-by-count":1,"title":["Low Generic Drug Penetration for Expensive Oral Molecular Targeted Agents: An Experience with Generic Imatinib in Japan"],"prefix":"10.2169","volume":"65","author":[{"given":"Keisuke","family":"Kidoguchi","sequence":"first","affiliation":[{"name":"Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Ureshino","sequence":"additional","affiliation":[{"name":"Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Kimura","sequence":"additional","affiliation":[{"name":"Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Ministry of Health, Labour and Welfare. Annual summary of vital statistics monthly report in 2022 [Internet]. [cited 2024 Jun 11]. Available from: https:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/jinkou\/geppo\/nengai22\/dl\/gaikyouR4.pdf (in Japanese)"},{"key":"2","unstructured":"2. Ministry of Health, Labour and Welfare. Overview of the national health expenditure in 2021 [Internet]. [cited 2024 Jun 11]. Available from: https:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/k-iryohi\/21\/dl\/data.pdf (in Japanese)"},{"key":"3","unstructured":"3. Ministry of Health, Labour and Welfare. Percentage of generic drugs by insurer in September 2021 [Internet]. [cited 2024 Jun 11]. Available from: https:\/\/www.mhlw.go.jp\/stf\/newpage_25028.html (in Japanese)"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Bower H, Bj\u00f6rkholm M, Dickman PW, H\u00f6glund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol 34: 2851-2857, 2016.","DOI":"10.1200\/JCO.2015.66.2866"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Ureshino H, Kamachi K, Kimura S. Japan's high-cost medical expense benefit system could be an obstacle to promoting generic imatinib. Lancet Haematol 6: e498, 2016.","DOI":"10.1016\/S2352-3026(19)30168-1"},{"key":"6","unstructured":"6. Ministry of Health, Labour and Welfare. Forecast of national health care cost in Japan [Internet]. [cited 2024 Jun 28]. Available from: https:\/\/www.mhlw.go.jp\/content\/12600000\/000536591.pdf (in Japanese)"},{"key":"7","unstructured":"7. CML Patient Survey Report by Izumi-no-kai in 2021 [Internet]. [cited 2024 Jun 11]. Available from: https:\/\/www.izumi-cml.jp\/pdf\/2021_CMLsurvey_izumi.pdf (in Japanese)"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34: 966-984, 2020.","DOI":"10.1038\/s41375-020-0776-2"},{"key":"9","unstructured":"9. The Japanese Society of Hematology. The JSH practical guidelines for hematological malignancies. (Version 2023) [Internet]. [cited 2024 Jun 11]. Available from: http:\/\/www.jshem.or.jp\/gui-hemali\/table.html (in Japanese)"},{"key":"10","unstructured":"10. NCCN Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia, Version 2.2024 [Internet]. [cited 2024 Jun 11]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cml.pdf"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Iriyama N, Iwanaga E, Kimura Y, et al. Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group. Int J Hematol 120: 60-70, 2024.","DOI":"10.1007\/s12185-024-03758-4"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Jabbour EJ, Mendiola MF, Lingohr-Smith M, Lin J, Makenbaeva D. Economic modeling to evaluate the impact of chronic myeloid leukemia therapy management on the oncology care model in the US. J Med Econ 22: 1113-1118, 2019.","DOI":"10.1080\/13696998.2019.1618316"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kantarjian H, Paul S, Thakkar J, Jabbour E. The influence of drug prices, new availability of inexpensive generic imatinib, new approvals, and post-marketing researchon the treatment of chronic myeloid leukaemia in the USA. Lancet Haematol 9: e854-e861, 2022.","DOI":"10.1016\/S2352-3026(22)00246-0"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Papanicolas I, Woskie LR, Jha AK. Health care spending in the United States and other high-income countries. JAMA 319: 1024-1039, 2018.","DOI":"10.1001\/jama.2018.1150"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Saugues S, Lambert C, Daguenet E, et al. Real-world therapeutic response and tyrosine kinase inhibitor discontinuation in chronic phase-chronic myeloid leukemia: data from the French observatory. Ann Hematol 101: 2241-2255, 2022.","DOI":"10.1007\/s00277-022-04955-z"},{"key":"16","unstructured":"16. Chinese Society of Hematology, Chinese Medical Association. The guidelines for diagnosis and treatment of chronic myelogenous leukemia in China (2020 edition). Zhonghua Xue Ye Xue Za Zhi 41: E001, 2020 (in Chinese)."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. \u0106ojba\u0161i\u0107 I, Ma\u010dukanovi\u0107-Golubovi\u0107 L, Vu\u010di\u0107 M, \u0106ojba\u0161i\u0107 \u017d. Generic imatinib in chronic myeloid leukemia treatment: long-term follow-up. Clin Lymphoma Myeloma Leuk 19: e526-e531, 2019.","DOI":"10.1016\/j.clml.2019.05.006"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Er\u00e7al\u0131\u015fkan A, Seyhan Erdo\u011fan D, E\u015fkazan AE. Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs. Blood Adv 5: 3344-3353, 2021.","DOI":"10.1182\/bloodadvances.2021004194"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Scalzulli E, Colafigli G, Latagliata R, et al. Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients. Ann Hematol 99: 2773-2777, 2020.","DOI":"10.1007\/s00277-020-04096-1"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Yang YT, Nagai S, Chen BK, et al. Generic oncology drugs: are they all safe? Lancet Oncol 17: e493-e501, 2016.","DOI":"10.1016\/S1470-2045(16)30384-9"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Yokoo M, Kubota Y, Tabe Y, Kimura S. Comparative study of the anti-leukemic effects of imatinib mesylate, Glivec\u2122 tablet and its generic formulation, OHK9511. Biol Pharm Bull 38: 411-416, 2015.","DOI":"10.1248\/bpb.b14-00652"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Walsh BS, Kesselheim AS, Sarpatwari A, Rome BN. Indication-specific generic uptake of imatinib demonstrates the impact of skinny labelling. J Clin Oncol 40: 1102-1110, 2022.","DOI":"10.1200\/JCO.21.02139"},{"key":"23","unstructured":"23. Ministry of Health, Labour and Welfare. Selective Treatment Fee for brand-name drugs with generic drugs [Internet]. [cited 2024 Jun 11]. Available from: https:\/\/www.mhlw.go.jp\/stf\/newpage_39830.html (in Japanese)"},{"key":"24","unstructured":"24. Ministry of Health, Labour and Welfare. Agenda for the 172nd session of the medical insurance subcommittee of the social security council [Internet]. [cited 2024 Jun 11]. Available from: https:\/\/www.mhlw.go.jp\/content\/12401000\/001178993.pdf (in Japanese)"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Khan HM, Ramsey S, Shankaran V. Financial toxicity in cancer care: implications for clinical care and potential practice solutions. J Clin Oncol 41: 3051-3058, 2023.","DOI":"10.1200\/JCO.22.01799"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Kimura S, Imagawa J, Murai K, et al.; DADI Trial Group. Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial. Lancet Haematol 7: e318-e325, 2020.","DOI":"10.1016\/S2352-3026(19)30235-2"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Yamamoto C, Nakashima H, Ikeda T, et al. Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation. Blood Adv 3: 3266-3277, 2019.","DOI":"10.1182\/bloodadvances.2019000745"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Yamazki K, Inagaki N, Moldaver D, Viana R, Kimura S. Budget impact analysis of treatment-free remission in nilotinib treated Japanese chronic myeloid leukemia patients. Cancer Sci 111: 2526-2535, 2020.","DOI":"10.1111\/cas.14430"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/6\/65_5182-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T03:33:16Z","timestamp":1774063996000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/6\/65_5182-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,15]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5182-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,15]]},"article-number":"5182-24"}}